Apatinib Plus Temozolomide for Recurrent Glioblastoma: An Uncontrolled, Open-Label Study
OncoTargets and Therapy - New Zealand
doi 10.2147/ott.s226804
Full Text
Open PDFAbstract
Available in full text
Date
December 1, 2019
Authors
Publisher
Informa UK Limited